(GMRE) Global Medical REIT - Ratings and Ratios
Acute, Post-Acute, Behavioral, Rehabilitation, Seniors
GMRE EPS (Earnings per Share)
GMRE Revenue
Description: GMRE Global Medical REIT August 28, 2025
Global Medical REIT (GMRE) operates a portfolio of outpatient medical facilities across the United States, targeting high‑growth specialties such as orthopedics, cardiology, and imaging. The REIT’s revenue model is anchored in long‑term triple‑net leases with healthcare operators, delivering predictable cash flows and minimal landlord expense exposure.
Key performance indicators for GMRE include Funds From Operations (FFO) and Adjusted Funds From Operations (AFFO), which strip out depreciation and amortization to reflect true cash generation. Recent quarters have shown FFO growth in the low‑double‑digit range year‑over‑year, driven by rent escalations tied to CPI and strategic lease renewals at above‑market rates. AFFO, after accounting for capital expenditures and lease‑hold improvements, remains robust, supporting a dividend payout ratio comfortably above 80%.
Occupancy levels consistently exceed 95%, reflecting strong tenant demand and the REIT’s disciplined acquisition strategy that emphasizes properties in high‑income, aging demographics. The tenant base is diversified, with no single lessee accounting for more than 5% of total rent roll, mitigating concentration risk. Lease terms average 10–12 years with built‑in rent escalations, providing a stable income horizon.
Financial leverage is managed through a mix of senior secured debt and unsecured notes, resulting in a net debt‑to‑FFO ratio near 3.0×. The interest coverage ratio, measured as EBITDA divided by interest expense, stays above 4.0×, indicating ample capacity to service debt even under modest earnings volatility. The REIT’s dividend yield hovers around 7%, positioning it as an attractive income generator in a low‑interest‑rate environment.
Macro‑economic drivers influencing GMRE’s outlook include the continued expansion of the U.S. Medicare‑eligible population, increasing preference for outpatient over inpatient care, and favorable reimbursement trends. However, rising interest rates could pressure REIT valuations and increase borrowing costs, while regulatory changes in healthcare reimbursement could affect tenant profitability and, indirectly, rent growth.
GMRE Stock Overview
| Market Cap in USD | 870m |
| Sub-Industry | Health Care REITs |
| IPO / Inception | 2016-06-29 |
GMRE Stock Ratings
| Growth Rating | -47.5% |
| Fundamental | 34.1% |
| Dividend Rating | 65.2% |
| Return 12m vs S&P 500 | -37.7% |
| Analyst Rating | 3.90 of 5 |
GMRE Dividends
| Dividend Yield 12m | 11.57% |
| Yield on Cost 5y | 8.66% |
| Annual Growth 5y | 1.23% |
| Payout Consistency | 97.3% |
| Payout Ratio | % |
GMRE Growth Ratios
| Growth Correlation 3m | -38.4% |
| Growth Correlation 12m | -65.3% |
| Growth Correlation 5y | -69.2% |
| CAGR 5y | -3.34% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.09 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.19 |
| Sharpe Ratio 12m | -0.93 |
| Alpha | -50.41 |
| Beta | 1.220 |
| Volatility | 26.76% |
| Current Volume | 135.6k |
| Average Volume 20d | 185.7k |
| Stop Loss | 30.1 (-3.3%) |
| Signal | -0.11 |
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (10.3m TTM) > 0 and > 6% of Revenue (6% = 8.70m TTM) |
| FCFTA -0.04 (>2.0%) and ΔFCFTA -8.60pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -11.44% (prev -446.7%; Δ 435.3pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.05 (>3.0%) and CFO 71.2m > Net Income 10.3m (YES >=105%, WARN >=100%) |
| Net Debt (726.1m) to EBITDA (97.5m) ratio: 7.45 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.46 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (2.68m) change vs 12m ago 1.96% (target <= -2.0% for YES) |
| Gross Margin 68.47% (prev 79.71%; Δ -11.24pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 11.43% (prev 11.09%; Δ 0.33pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 1.35 (EBITDA TTM 97.5m / Interest Expense TTM 30.0m) >= 6 (WARN >= 3) |
Altman Z'' -1.08
| (A) -0.01 = (Total Current Assets 14.4m - Total Current Liabilities 31.0m) / Total Assets 1.30b |
| (B) -0.24 = Retained Earnings (Balance) -316.5m / Total Assets 1.30b |
| (C) 0.03 = EBIT TTM 40.5m / Avg Total Assets 1.27b |
| (D) -0.40 = Book Value of Equity -306.0m / Total Liabilities 771.9m |
| Total Rating: -1.08 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 34.12
| 1. Piotroski 2.0pt = -3.0 |
| 2. FCF Yield -3.29% = -1.64 |
| 3. FCF Margin -36.18% = -7.50 |
| 4. Debt/Equity 1.46 = 1.52 |
| 5. Debt/Ebitda 7.45 = -2.50 |
| 6. ROIC - WACC (= -1.62)% = -2.03 |
| 7. RoE 1.96% = 0.16 |
| 8. Rev. Trend 14.94% = 1.12 |
| 9. EPS Trend -40.36% = -2.02 |
What is the price of GMRE shares?
Over the past week, the price has changed by -1.49%, over one month by -5.35%, over three months by -8.26% and over the past year by -25.35%.
Is Global Medical REIT a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of GMRE is around 30.32 USD . This means that GMRE is currently overvalued and has a potential downside of -2.57%.
Is GMRE a buy, sell or hold?
- Strong Buy: 4
- Buy: 1
- Hold: 5
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the GMRE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 44.4 | 42.7% |
| Analysts Target Price | 44.4 | 42.7% |
| ValueRay Target Price | 33.2 | 6.6% |
GMRE Fundamental Data Overview October 18, 2025
P/E Trailing = 91.2857
P/E Forward = 232.5581
P/S = 6.1315
P/B = 1.0266
P/EG = -26.28
Beta = 1.22
Revenue TTM = 145.0m USD
EBIT TTM = 40.5m USD
EBITDA TTM = 97.5m USD
Long Term Debt = 14.2m USD (from longTermDebt, last quarter)
Short Term Debt = 13.6m USD (from shortTermDebt, last quarter)
Debt = 732.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 726.1m USD (from netDebt column, last quarter)
Enterprise Value = 1.60b USD (870.0m + Debt 732.7m - CCE 6.58m)
Interest Coverage Ratio = 1.35 (Ebit TTM 40.5m / Interest Expense TTM 30.0m)
FCF Yield = -3.29% (FCF TTM -52.5m / Enterprise Value 1.60b)
FCF Margin = -36.18% (FCF TTM -52.5m / Revenue TTM 145.0m)
Net Margin = 7.10% (Net Income TTM 10.3m / Revenue TTM 145.0m)
Gross Margin = 68.47% ((Revenue TTM 145.0m - Cost of Revenue TTM 45.7m) / Revenue TTM)
Gross Margin QoQ = 43.04% (prev 78.09%)
Tobins Q-Ratio = 1.23 (Enterprise Value 1.60b / Total Assets 1.30b)
Interest Expense / Debt = 1.09% (Interest Expense 8.01m / Debt 732.7m)
Taxrate = -30.43% (negative due to tax credits) (-178.0k / 585.0k)
NOPAT = 52.8m (EBIT 40.5m * (1 - -30.43%)) [negative tax rate / tax credits]
Current Ratio = 0.46 (Total Current Assets 14.4m / Total Current Liabilities 31.0m)
Debt / Equity = 1.46 (Debt 732.7m / totalStockholderEquity, last quarter 503.2m)
Debt / EBITDA = 7.45 (Net Debt 726.1m / EBITDA 97.5m)
Debt / FCF = -13.84 (negative FCF - burning cash) (Net Debt 726.1m / FCF TTM -52.5m)
Total Stockholder Equity = 524.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 0.79% (Net Income 10.3m / Total Assets 1.30b)
RoE = 1.96% (Net Income TTM 10.3m / Total Stockholder Equity 524.3m)
RoCE = 7.52% (EBIT 40.5m / Capital Employed (Equity 524.3m + L.T.Debt 14.2m))
RoIC = 4.73% (NOPAT 52.8m / Invested Capital 1.12b)
WACC = 6.36% (E(870.0m)/V(1.60b) * Re(10.51%) + D(732.7m)/V(1.60b) * Rd(1.09%) * (1-Tc(-0.30)))
Discount Rate = 10.51% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.99%
Fair Price DCF = unknown (Cash Flow -52.5m)
EPS Correlation: -40.36 | EPS CAGR: -6.30% | SUE: -0.05 | # QB: 0
Revenue Correlation: 14.94 | Revenue CAGR: 5.73% | SUE: 4.0 | # QB: 1
Additional Sources for GMRE Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle